Variants Other Than Aspartic Acid at Codon 69 of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene Affect Susceptibility to Nuleoside Analogs

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2001 Jul 14

PMID 11451685

Citations 13

Authors

M A Winters

T C Merigan

Affiliations

Soon will be listed here.

Abstract

The T69D mutation in the human immunodeficiency virus type 1 reverse transcriptase (RT) gene has been associated with reduced susceptibility to dideoxycytosine (ddC); however, several other mutations at codon 69 have been observed in antiretroviral drug-treated patients. The Stanford HIV RT and Protease Sequence Database was interrogated and showed that 23% of patients treated with nucleoside RT inhibitors (NRTI) had mutations at codon 69. These variants included T69N, -S, -A, -G, -E, -I, and -K mutations that were present in patients treated with NRTI but not in drug-naive patients. Treatment history information showed that a substantial percentage of these codon 69 changes occurred in patients administered non-ddC-containing regimens. Different and specific patterns of other RT gene mutations were associated with the various codon 69 mutations. Drug susceptibility assays showed that viral constructs containing codon 69 variants could have reduced susceptibility to ddC and other RT inhibitors. These results suggest that the T69D mutation is not the only codon 69 variant associated with drug resistance and that ddC is not the only drug affected.

Citing Articles

HIV-1 subtypes and drug resistance profiles in a cohort of heterosexual patients in Istanbul, Turkey.

Koksal M, Beka H, Lubke N, Verheyen J, Eraksoy H, Cagatay A Med Microbiol Immunol. 2015; 204(4):551-5.

PMID: 25916350 DOI: 10.1007/s00430-015-0419-9.

A counting renaissance: combining stochastic mapping and empirical Bayes to quickly detect amino acid sites under positive selection.

Lemey P, Minin V, Bielejec F, Kosakovsky Pond S, Suchard M Bioinformatics. 2012; 28(24):3248-56.

PMID: 23064000 PMC: 3579240. DOI: 10.1093/bioinformatics/bts580.

Unusual insertion and deletion at codon 67 and 69 of HIV type 1 subtype C reverse transcriptase among first-line highly active antiretroviral treatment-failing South Indian patients: association with other resistance mutations.

Saravanan S, Madhavan V, Kantor R, Sivamalar S, Gomathi S, Solomon S AIDS Res Hum Retroviruses. 2012; 28(12):1763-5.

PMID: 22404052 PMC: 3505055. DOI: 10.1089/AID.2011.0331.

A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Shafer R, Dupnik K, Winters M, Eshleman S HIV Seq Compend. 2012; 2001:1-51.

PMID: 22324021 PMC: 3274565.

Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors.

Smith R, Gottlieb G, Miller A Retrovirology. 2010; 7:70.

PMID: 20807431 PMC: 2939604. DOI: 10.1186/1742-4690-7-70.

References

Boucher C, OSullivan E, Mulder J, Ramautarsing C, Kellam P, Darby G . Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis. 1992; 165(1):105-10. DOI: 10.1093/infdis/165.1.105. View

St Clair M, Martin J, Tudor-Williams G, Bach M, Vavro C, King D . Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science. 1991; 253(5027):1557-9. DOI: 10.1126/science.1716788. View

Tantillo C, Ding J, Nanni R, Boyer P, Hughes S, Pauwels R . Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol. 1994; 243(3):369-87. DOI: 10.1006/jmbi.1994.1665. View

Larder B, Kemp S, Harrigan P . Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 1995; 269(5224):696-9. DOI: 10.1126/science.7542804. View

Winters M, Coolley K, Girard Y, Levee D, Hamdan H, Shafer R . A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest. 1998; 102(10):1769-75. PMC: 509125. DOI: 10.1172/JCI4948. View

Arion D, Kaushik N, McCormick S, Borkow G, Parniak M . Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry. 1998; 37(45):15908-17. DOI: 10.1021/bi981200e. View

Boyer P, Lisziewicz J, Lori F, Hughes S . Analysis of amino insertion mutations in the fingers subdomain of HIV-1 reverse transcriptase. J Mol Biol. 1999; 286(4):995-1008. DOI: 10.1006/jmbi.1998.2508. View

de Jong J, Goudsmit J, Lukashov V, Hillebrand M, Baan E, Huismans R . Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS. 1999; 13(1):75-80. DOI: 10.1097/00002030-199901140-00010. View

Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P . Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 1999; 353(9171):2195-9. DOI: 10.1016/s0140-6736(98)12291-2. View

10.

Larder B, Bloor S, Kemp S, Hertogs K, Desmet R, Miller V . A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob Agents Chemother. 1999; 43(8):1961-7. PMC: 89398. DOI: 10.1128/AAC.43.8.1961. View

11.

Fitzgibbon J, Howell R, Haberzettl C, Sperber S, Gocke D, DUBIN D . Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine. Antimicrob Agents Chemother. 1992; 36(1):153-7. PMC: 189244. DOI: 10.1128/AAC.36.1.153. View

12.

CARPENTER C, Cooper D, Fischl M, Gatell J, Gazzard B, Hammer S . Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2000; 283(3):381-90. DOI: 10.1001/jama.283.3.381. View

13.

Hirsch M, Brun-Vezinet F, DAquila R, Hammer S, Johnson V, Kuritzkes D . Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA. 2000; 283(18):2417-26. DOI: 10.1001/jama.283.18.2417. View

14.

Degruttola V, Dix L, DAquila R, Holder D, Phillips A, Ait-Khaled M . The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther. 2000; 5(1):41-8. DOI: 10.1177/135965350000500112. View

15.

Baxter J, Mayers D, Wentworth D, Neaton J, HOOVER M, Winters M . A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 2000; 14(9):F83-93. DOI: 10.1097/00002030-200006160-00001. View

16.

Perez-Elias M, Lanier R, Munoz V, Garcia-Arata I, Casado J, Marti-Belda P . Phenotypic testing predicts virological response in successive protease inhibitor-based regimens. AIDS. 2000; 14(9):F95-101. DOI: 10.1097/00002030-200006160-00002. View

17.

Kantor R, Machekano R, GONZALES M, Dupnik K, Schapiro J, Shafer R . Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs. Nucleic Acids Res. 2000; 29(1):296-9. PMC: 29795. DOI: 10.1093/nar/29.1.296. View

18.

Larder B, Kemp S . Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989; 246(4934):1155-8. DOI: 10.1126/science.2479983. View